December 12, 2016 10:11 AM ESTUpdated 11:55 AM

As FDA assesses its antibiotic, Cempra bids longtime CEO Prabha Fernandes goodbye

Arsalan Arif

Founder

Just weeks after an expert panel unenthusiastically endorsed its new antibiotic solithromycin, Cempra $CEMP has chosen to switch out CEOs. Company co-founder and CEO …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As FDA assesses its antibiotic, Cempra bids longtime CEO Prabha Fernandes goodbye

Arsalan Arif

Founder

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

As FDA as­sess­es its an­tibi­ot­ic, Cem­pra bids long­time CEO Prab­ha Fer­nan­des good­bye

Arsalan Arif

Founder

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

As FDA assesses its antibiotic, Cempra bids longtime CEO Prabha Fernandes goodbye

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva